Ainos Overview
Is AIMD undervalued? Intrinsic value estimate stands at $-0.9.
Get informed when a big investor buys or sells
+ Follow$-0.90
Overvalued by 167.1% based on the discounted cash flow analysis.
Ainos (AIMD) currently reports a DCF fair value of $-0.9. Use the charts on this page to explore Ainos's DCF fair value history and peer comparisons.
Ainos's discounted cash flow (DCF) fair value estimate is $-0.9, about 167.1% overvalued versus the current market price. DCF models project future free cash flows and discount them back to today — so the result depends on growth, margin, and discount-rate assumptions. Use it as one valuation lens alongside multiples and peer checks on Stockcircle.
Start with the current DCF fair value of $-0.9, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Ainos, and consider following AIMD for alerts when major investors trade the stock.
Ainos is classified in the Healthcare sector. On DCF fair value, it currently shows $-0.9. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AIMD with unrelated industries.
